A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...
for its Abbreviated New Drug Application (ANDA) for ipratropium bromide nasal solution (nasal spray), 0.06%, to market a generic equivalent of Atrovent nasal spray, 0.06%, of Boehringer Ingelheim ...